Keywords
lncRNA
Prognosis
Resistance
GAS5
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify lncRNAs associated with chemotherapy resistance in cervical cancer (CC). Methods: This study is a systematic literature review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol was previously registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the code CRD42023432017. Searches were performed in databases such as PubMed, ScienceDirect, and Web of Science, resulting in the selection of 21 articles published between 2017 and 2023. Results: The findings highlighted that 19 lncRNAs are implicated in resistance to four chemotherapeutic agents, including GAS5, which was the target of the greatest number of studies. These lncRNAs are involved in resistance to paclitaxel (PTX), 5-fluorouracil (5-FU), and doxorubicin (DTX). Final considerations: These results underscore the importance of lncRNAs as potential markers of treatment response and suggest that miRNA-mediated regulation may directly influence biological pathways that are frequently dysregulated in cancer.
References
BHATTACHARJEE R, et al. Cellular landscaping of cisplatin resistance in cervical cancer. Biomed Pharmacother, 2022; 153: 113345.
BRAY F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018; 68(6): 394–424.
BRANDÃO HN, et al. Química e farmacologia de quimioterápicos antineoplásicos derivados de plantas. Quim Nova, 2010; 33(6): 1359–69.
CAO S, et al. Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. Int J Clin Exp Pathol, 2014; 7(10): 6776–83.
CHEN W, et al. Nomogram for prognosis of elderly patients with cervical cancer who receive combined radiotherapy. Sci Rep, 2023; 13(1): 13299.
DU Y, et al. LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis. BMC Cancer, 2022; 22(1): 1145.
FANG X, et al. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death Dis, 2020; 11(7): 531.
FARZANEH M, et al. Emerging roles of the long non-coding RNA NEAT1 in gynecologic cancers. J Cell Commun Signal, 2023; 17(3): 531–47.
FENG L-L, et al. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity. Gene, 2019; 696: 105–12.
GHOSH S. Cisplatin: The first metal based anticancer drug. Bioorg Chem, 2019; 88: 102925.
GIDDINGS EL, et al. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nat Commun, 2021; 12(1): 2804.
HE J, et al. Long non-coding RNA in cervical cancer: From biology to therapeutic opportunity. Biomed Pharmacother, 2020; 127: 110209.
HE S, et al. The role of the SOX9/lncRNA ANXA2P2/miR-361-3p/SOX9 regulatory loop in cervical cancer cell growth and resistance to cisplatin. Front Oncol, 2021; 11: 784525.
INSTITUTO NACIONAL DE CÂNCER (INCA). Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2023.
JOHNSON CA, et al. Cervical cancer: An overview of pathophysiology and management. Semin Oncol Nurs, 2019; 35(2): 166–74.
LIU M, et al. Expression of micro-RNA-492 (MiR-492) in human cervical cancer cell lines is upregulated by transfection with wild-type P53, irradiation, and 5-fluorouracil treatment in vitro. Med Sci Monit, 2018; 24: 7750–8
.
LIU MY, LI N. The diagnostic value of lncRNA HOTAIR for cervical carcinoma in vaginal discharge and serum. Medicine (Baltimore), 2023; 102(26): e34042.
LIU S, et al. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett, 2022; 528: 16–30.
LUO X, et al. Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis. Cancer Cell Int, 2019; 19: 323.
MAO B-D, et al. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J Biosci, 2019; 44(2).
MARKMAN M. Advances in cervical cancer pharmacotherapies. Expert Rev Clin Pharmacol, 2014; 7(2): 219–23.
MECENAS P, et al. Effects of temperature and humidity on the spread of COVID-19: A systematic review. PLoS One, 2020; 15(9): e0238339.
METHLEY AM, et al. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res, 2014; 14(1): 579.
MODABBER N, et al. Evaluation of long non-coding RNA (lncRNA) in the pathogenesis of chemotherapy resistance in cervical cancer: diagnostic and prognostic approach. Mol Biotechnol, 2024; 66(10): 2751–2763.
ORGANIZAÇÃO PAN-AMERICANA DA SAÚDE (OPAS). Câncer do colo do útero. Washington, DC: OPAS.
PAGE MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021; 372: n71.
PAVLOVA NN, THOMPSON CB. The emerging hallmarks of cancer metabolism. Cell Metab, 2016; 23(1): 27–47.
QU S, et al. MiR-361-3p regulates liver tumor-initiating cells expansion and chemo-resistance. J Cancer, 2021; 12(5): 1483–92.
SAW PE, et al. Non-coding RNAs: the new central dogma of cancer biology. Sci China Life Sci, 2021; 64(1): 22–50.
SETHY C, KUNDU CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother, 2021; 137: 111285.
SHAO X, et al. Inhibition of lncRNA-NEAT1 sensitizes 5-Fu resistant cervical cancer cells through de-repressing the microRNA-34a/LDHA axis. Biosci Rep, 2021; 41(7).
SHEN C-J, et al. LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target, 2017; 25(7): 637–44.
SWEEF O, et al. Decoding lncRNA in COPD: unveiling prognostic and diagnostic power and their driving role in lung cancer progression. Int J Mol Sci, 2024; 25(16): 9001.
WAN S, ZHAO H. Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer. Oncol Lett, 2020; 20(5): 183.
WEN Q, et al. Long noncoding RNA GAS5, which acts as a tumor suppressor via microRNA 21, regulates cisplatin resistance expression in cervical cancer. Int J Gynecol Cancer, 2017; 27(6): 1096–108.
YAO T, et al. Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21. J Cell Physiol, 2019; 234(6): 9605–15.
YUAN LY, et al. Involvement of NEAT1/miR-133a axis in promoting cervical cancer progression via targeting SOX4. J Cell Physiol, 2019; 234(10): 18985–18993.
ZHANG L, et al. LncRNA SNHG5 promotes cervical cancer progression by regulating the miR-132/SOX4 pathway. Autoimmunity, 2021; 54(2): 88–96.
ZHANG W, et al. LncRNA HOTAIR promotes chemoresistance by facilitating epithelial to mesenchymal transition through miR-29b/PTEN/PI3K signaling in cervical cancer. Cells Tissues Organs, 2022; 211(1): 16–29.
ZHANG Y, WEN Y. The role of lncRNA NEAT1 in gastric cancer: tumor development and potential therapeutic target. Curr Pharm Des, 2023; 29(28): 2213–22.
ZHOU C, et al. Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): A phase 3, open-label, randomized controlled trial. J Thorac Oncol, 2023; 18(1): 93–105.